

Molecular identification of *Scedosporium* species from CF patients and in vitro susceptibility of the novel antifungal compound F901318

Steeg D, Hagen F, Chowdhary A, Verweij PE, Meis JF

¹Center of Expertise in Mycology, Radboudumc/Canisius Wilhelmina Hospital, NIJMEGEN, Netherlands, ²Department of Mycology, VP Chest Institute, DELHI, India

Introduction

Scedosporium spp. and relatives are among the fungi with resistance to many conventional antifungal compounds and which rank second among filamentous fungi colonizing cystic fibrosis (CF) patients.

F901318¹, a first [2561.64i/0 T 0 Tc 0 Tw 35407 0 Td [rmerent-.2(a)-1.5(t)0.5(vey)]TJ -0.001 Tc 0.038 Tw 6.725

Materials and Methods

Results

Conclusion

F901318 demonstrated potent in vitro activity against *Scedosporium* species and *L. prolificans* confirming an earlier study.³ Clinical studies are warranted to evaluate the efficacy of F901318 against difficult to treat *Scedosporium* infections.